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APhase III trial on the efﬁcacy of bevacizumab in recurrent glioblastoma patients.
Shows that patients may be able to defer bevacizumab use without diminishing overall survival time.
A randomized Phase II trial analyzing the effect of bevacizumab treatment on overall survival in recurrent grade II and -III
glioma patients.
Suggests that tumor burden before bevacizumab initiation can have prognostic value in glioblastoma patients.
Suggests that treatment continuation beyond initial recurrence on treatment may provide modest survival improvement in
recurrent glioblastoma patients when compared with other nonbevacizumab therapies.
Interestingly shows that IDH mutation does not seem to impart long-term survival to glioblastoma patients ( 4 years) even
though it is important in terms of short-term survival. MGMT methylation status is also shown to have prognostic value beyond
4 years.
Highlights genetic alterations, such as ATRX and PDGFRA, that may have prognostic value for long-term surviving glioblastoma
patients.
